Encyclopedia entry
Bariatric surgery vs GLP-1 medications
Bariatric surgery and GLP-1 medications are complementary NHS weight management pathways, not competing alternatives. GLP-1 prescribing sits at Tier 3 in the NHS framework; bariatric surgery sits at Tier 4. The standard NHS sequence is: Tier 3 trial first, Tier 4 escalation if outcomes are insufficient. Both pathways have distinct strengths.
Typical weight loss
- · Mounjaro at maintenance dose: 20–22 percent average weight loss over 72 weeks (SURMOUNT-1).
- · Wegovy at maintenance dose: 14–15 percent average over 68 weeks (STEP-1).
- · Gastric sleeve: 25–30 percent total body weight loss at 12 to 24 months, typically sustained.
- · Gastric bypass: 30–35 percent total body weight loss at 12 to 24 months.
- · Gastric band: 15–20 percent, less commonly performed in 2026 due to revision rates.
Strengths and trade-offs
- GLP-1 medications: non-invasive, reversible (stop the medication and regain typically follows within 12 to 18 months), broadly tolerated, ongoing monthly cost or NHS-funded if eligible.
- Bariatric surgery: one-time intervention with one-time cost, sustained outcomes if the patient maintains the dietary changes, but surgical risk, irreversible anatomical change (for sleeve and bypass), and requires lifelong nutritional supplementation.
Can GLP-1 follow bariatric surgery
Yes. Post-bariatric weight regain is common (20 to 30 percent of patients regain meaningful weight by year 5). GLP-1 prescribing for post-bariatric regain is increasingly common in 2026, both privately and through NHS Tier 3 routes. The two are stacked rather than substituted.
Related: Tier 3 / Tier 4 · NICE TA1026.